-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Scientists at the University of Cambridge and the University of Leeds have successfully reversed age-related memory loss in mice, and said their findings may help develop treatments that prevent memory loss in humans as they age
In a study published today in the journal Molecular Psychiatry, the team showed that changes in the brain’s extracellular matrix (the "scaffolding" around nerve cells) can lead to memory loss with age, but it is possible through Gene therapy to reverse these changes
There is recent evidence that peripheral neural networks (PNNs) play a role in neuroplasticity (the brain’s ability to learn and adapt) and memory
pns contains chondroitin sulfate compounds
Researchers from the University of Cambridge and the University of Leeds investigated whether manipulating the chondroitin sulfate component of PNNs might restore neuroplasticity and reduce age-related memory deficits
To do this, the research team observed 20-month-old mice (which are considered very old) and used a series of tests.
For example, one test involves observing whether a mouse recognizes an object
The research team used a "viral vector" to treat aging mice.
Dr.
In order to explore the role of chondroitin sulfate in memory loss, the researchers bred genetically manipulated mice so that they could only produce low levels of this compound to mimic the changes in the aging process
Professor James Fawcett’s John Van Episcopal Brain Repair Center at the University of Cambridge said: “What’s exciting is that although our research is only in mice, the same mechanism should be in humans-the human brain.
The team has identified a potential drug that can be taken orally and inhibit the formation of PNNs, and has obtained permission for human use
The method used by Professor Fawcett's team-the use of viral vectors for treatment-is increasingly being used to treat human neurological diseases